Inhalation Sciences Q4 2022: In line with our expectations - Redeye

Redeye provides an update in relation to ISAB’s Q4 2022 report. Full-year sales came in at SEK12.2m (SEK9.4m) and EBIT at SEK-12.0m (SEK-16.6m). We have chosen to make some changes in our model, mainly changes in sales and OPEX, and included an equity issue during 2023. This results in a new fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/886595/inhalation-sciences-q4-2022-in-line-with-our-expectations?utm_source=finwire&utm_medium=RSS